MarginsXMarginsX
Home › Markets › Health Care › PTHS

Pelthos Therapeutics Inc. (PTHS)

PTHS trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.15
-3.90% on the day
Market cap
$28.1M
Nano cap
Revenue · 2025
$16.8M
Prior year not contiguous
Net income · 2025
-$43.3M
-257.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/0001919246-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPTHS on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryNot reported by the screener
IPO year2024
SEC CIK0001919246
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNV

Financials · 2025

LineValue
Revenue$16.8M
Net income-$43.3M
Operating income-$32.4M
Net margin-257.9%
Operating margin-193.1%
Revenue growthNo prior-year revenue to compare
Cash$18.0M
Total assets$130.4M
P/E (computed)Net income was not positive
P/S (computed)1.7×

Warning signs

Cash runway
6.6 months
$17.7M cash at September 30, 2026
Share count, 1 year
+28.4%
2025-11-07 to 2026-11-05
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$558K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"The Company has evaluated principal conditions and events, in the aggregate, that may raise substantial doubt about its ability to continue as a going concern within one year from the date that these financial statements are issued."
10-Q 2026-11-12
Cash and burn$17.7M cash; operating cash flow -$8.1M a quarter.Report 2026-09-30
Shares outstanding3,930,709 (2026-11-05); 3,061,681 a year earlier.Cover page 2026-11-05
Reverse splits, 3 years1; latest 1-for-10 on 2025-07-02Source 2025-07-02
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Hartford, Connecticut, United States; changed auditors 2 times in 24 months8-K 4.01 2026-05-21
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1000K, sold $441K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$15.4M-$7.9M-$5.2M$17.7M$38.4M$51.3M10-Q 2026-11-12
Q2 2026
2026-06-30
$15.6M-$23.4M-$7.7M$24.2M$43.3M$43.3M10-Q 2026-08-13
Q1 2026
2026-03-31
$10.9M-$25.1M-$13.1M$32.0M$39.1M$27.7M10-Q/A 2026-08-13
Q4 2025
2025-12-31
$9.4M-$21.7M-$6.3M$18.0M$31.4M$16.8M10-K 2026-03-19
Q3 2025
2025-09-30
$7.4M-$16.2M-$15.3M$14.2MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
$0-$3.4M-$447K$59K$132KNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
$0-$2.0M-$632K$131K$132KNeeds four quarters10-Q/A 2026-08-13
Q4 2024
2024-12-31
Not filed-$1.9M-$670K$513K$132K$010-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-02-13
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-08-18

Source: SEC EDGAR submissions feed, 261 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-20.5%
1 month-63.3%
3 months-74.3%
Year to date-76.0%
1 year-78.5%
From 52-week high-77.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SAENGenenta Science S.p.A.$0.6000-7.66%$28.9M
CVMCel-Sci Corporation$1.66+29.69%$29.2M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
LONALeonaBio Inc.$3.23-6.92%$30.4M
MGXMetagenomi Therapeutics Inc.$0.6800-1.69%$25.7M
EVAXEvaxion A/S American Depositary Share$2.77+0.54%$25.5M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
ELUTElutia Inc.$0.8229+0.35%$36.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier